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(5R)-5-Hydroxytriptolide (LLDT-
8) induces substantial epigenetic 
mediated immune response 
network changes in fibroblast-like 
synoviocytes from rheumatoid 
arthritis patients
Shicheng Guo1, Jia Liu2,3, Ting Jiang2,3, Dungyang Lee4, Rongsheng Wang2,3, Xinpeng Zhou2, 
Yehua Jin2, Yi Shen2,3, Yan Wang3, Fengmin Bai2,3, Qin Ding2,3, Grace Wang5, Jianyong Zhang6, 
Xiaodong Zhou7, Steven J. Schrodi1,8 & Dongyi He2,3
Tripterygium is a traditional Chinese medicine that has widely been used in the treatment of rheumatic 
disease. (5R)-5-hydroxytriptolide (LLDT-8) is an extracted compound from Tripterygium, which has been 
shown to have lower cytotoxicity and relatively higher immunosuppressive activity when compared to 
Tripterygium. However, our understanding of LLDT-8-induced epigenomic impact and overall regulatory 
changes in key cell types remains limited. Doing so will provide critically important mechanistic 
information about how LLDT-8 wields its immunosuppressive activity. The purpose of this study was to 
assess the effects of LLDT-8 on transcriptome including mRNAs and long non-coding RNA (lncRNAs) 
in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) by a custom genome-wide microarray 
assay. Significant differential expressed genes were validated by QPCR. Our work shows that 394 
genes (281 down- and 113 up-regulated) were significantly differentially expressed in FLS responding 
to the treatment of LLDT-8. KEGG pathway analysis showed 20 pathways were significantly enriched 
and the most significantly enriched pathways were relevant to Immune reaction, including cytokine-
cytokine receptor interaction (P = 4.61 × 10−13), chemokine signaling pathway (P = 1.01 × 10−5) and 
TNF signaling pathway (P = 2.79 × 10−4). Furthermore, we identified 618 highly negatively correlated 
lncRNA-mRNA pairs from the selected significantly differential lncRNA and mRNA including 27 cis-
regulated and 591 trans-regulated lncRNA-mRNAs modules. KEGG and GO based function analysis 
to differential lncRNA also shown the enrichment of immune response. Finally, lncRNA-transcription 
factor (TF) and lncRNA-TF-mRNA co-expression network were constructed with high specific network 
characteristics, indicating LLDT-8 would influence the expression network within the whole FLS cells. 
The results indicated that the LLDT-8 would mainly influence the FLS cells systemically and specially in 
the process of immune related pathways.
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Rheumatoid arthritis (RA) is the most common chronic inflammatory disease with complex etiology1. The 
inflammation makes the synovium thicken and causes swelling around the joints. Thus, it induces the damage of 
cartilage. Recent findings indicate that remission of symptoms is more likely when treatment begins early with 
medications2. Although several widely-used anti-rheumatic drugs, such as methotrexate, steroids, anti-IL-6R and 
anti-TNFa monoclonal antibodies, have demonstrated some degree of efficacy in the treatment of RA, a substan-
tial proportion of patients exhibit poor response and the incidence of adverse reactions is substantial. The use of 
plant- and microbial-based compounds to treat a variety of pathologies has an extensive history and includes dig-
italis, L-Dopa, taxol, quinine, ephedrine, codeine, and penicillin3,4. In our clinical practice, we found a traditional 
Chinese medicine Tripterygium could be applied to decrease the severity of RA. Tripterygium is a genus of plants 
from the Euonymus Corey Gong. This Traditional Chinese medicine has been used in the treatment of auto-
immune disease5,6, rheumatic disease7,8, and systemic lupus erythematosus (SLE)9,10. Triptolide is an extracted 
compound from Tripterygium, which has strong immunosuppressive activity. Triptolide can inhibit interleukin-6 
(IL-6) and reduce osteoclastogenesis by inhibiting NF-κB signaling. An optimized structured analog of Triptolide, 
(5R)-5-hydroxytriptolide (LLDT-8), has been shown to have both low toxicity and high immunosuppressive abil-
ity11. Previous studies also demonstrated that LLDT-8 can suppress the immune responses on peripheral blood 
mononuclear cells (PBMC) and T cells11. Importantly, LLDT-8 also inhibited the differentiation of Th1 and Th17 
cells and has effect on the immune responses of RA patients12. Increasing evidence indicates that activated syno-
vial fibroblasts, together with macrophage and lymphocyte secreted factors, as part of a complex cellular network, 
play an important role in the pathogenesis of rheumatoid arthritis13. Meanwhile the effect of LLDT-8 to cells have 
been also validated in our previous report11 and other studies in vivo14 and in vitro experiments15–19. However, 
the pharmacological effect of LLDT-8 on synovial fibroblasts has not been investigated. Further, elucidating the 
underlying molecular mechanisms of how LLDT-8 generates immunosuppression without a high degree of tox-
icity may provide a platform for the development of novel anti-rheumatologic therapeutics.
Long non-coding RNAs (lncRNAs) are a recently discovered class of non-coding functional RNA and some 
important roles of lncRNAs as regulators in a wide spectrum of biological processes were identified in the past 
several years20–22. There are over 16,000 lncRNAs in humans and the functions of majority of them are unknown. 
Recent evidence also suggests the role of lncRNAs in the pathophysiology of disease processes, especially in 
cancer and immune disease23–27. In the previous studies, lncRNA have been reported to be related to the patho-
genesis of RA due to its association of major pathways linked to Inflammation, such as NFkB and TLR signaling26. 
However, whether lncRNA is involved in the mechanism of therapy of LLDT-8 to rheumatoid arthritis is still 
unknown.
The aim of this study was designed to identify the mechanism of immuno-impressive function of LLDT-8 and 
identify potential ncRNA targets of LLDT-8. We applied TNF-α and IL-17 to induce an inflammatory status in 
the cells so that we can observe the LLDT-8 effect easily compared with treatment to normal FLS cell directly. We 
then assessed the effects of LLDT-8 on the regulation of gene expression on mRNAs and long non-coding RNAs 
in FLS isolated from RA patients. Agilent Human lncRNA (4 × 180 K, Design ID: 062918) was applied in present 
study to provide genome-wide ncRNA and mRNA expression profile. With this study, we aimed to demonstrate 
how LLDT-8 treatment significantly impacts the process of immune regulation.
Material and Methods
Patients, cell culture and LLDT-8 treatment. FLS cells were derived from the synovial tissues of 
patients with RA in Guanghua hospital who had undergone total joint replacement surgery during June to August 
2015. Written informed consent to collect FLS cells for LLDT-8 studies was obtained from all participating RA 
patients. This study was approved by the academic advisory board of Guanghua Hospital (No. 2015-SRA-01) and 
all methods were performed in accordance with the relevant guidelines and regulations. All patients were random 
enrolled and all of them fulfilled the American College of Rheumatology classification criteria for RA28. Clinical 
data were collected at the time of sample collection. The detail clinical information is shown in Table 1.
An overview of the cellular processing is shown in Fig. 1. Briefly, joint tissues were minced into 1 × 1 × 1 mm 
pieces and treated for 2 hours (h) with 2–4 mg/ml of collagenase (Serva, GERMANY) in DMEM at 37 °C in 5% 
CO2. Dissociated cells were then centrifuged at 500 × g, re-suspended in DMEM supplemented with 10% FCS 
(Gibco, USA), and plated in 75 cm2 flasks. The cultures were kept at 37 °C in 5% CO2 and the culture medium 
was replaced every 2–3 days. Mycoplasma assay was performed on synovial fibroblasts to avoid mycoplasma con-
tamination. When cells approached confluence, they were passed after diluting 1:3 with fresh medium until used. 
The purity of the cells was verified by flow cytometric analysis. The FLS cells of passages 4th were seeded in 6-well 
plates. As the control group, the FLS cells were cultured in DMEM including 10 ng/ml TNF-α and 10 ng/ml IL-17 
ID COD(Year) SJC TJC ESR CRP PGA DAS28-CRP
RA-001 5 4 4 19 29.8 40 4.3
RA-002 20 10 10 27 25.97 70 5.66
RA-003 6 1 1 25 6.1 60 3.58
RA-004 8 1 2 11 1.3 60 3.05
RA-005 20 18 16 21 18 65 6.19
Table 1. Clinical and demographical Characteristics of 5 RA patients. COD: course of a disease; SJC: swollen 
joint count; TJC: tender joint count; ESR: erythrocyte sedimentation rate; PGA: patient global assessment; 
DAS28-CRP: disease activity score in 28 Joints.
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(PeproTech, USA) for 12 h. In the treatment group, LLDT-8 (Shanghai Pharma, Shanghai) was dissolved with 2% 
DMSO and diluted with DMEM (with TNF-α and IL-17) to 100 nm/ml for 24 hours. 100 nM LLDT-8 does not 
have obvious FLS cytotoxic effect while producing a slight apoptosis effect for FLS (Supplementary Fig. 1) which 
is consistent with a previous report11,29. In the process to validate the microarray data, TNF-α treatment was 
applied to simulate a pro-inflammatory reaction and then LLDT8 treatment was applied to evaluate the effect of 
LLDT-8 on the inflammatory reaction as measured by real-time PCR (RT-PCR).
RNA extraction and microarray hybridization. The total RNA was extracted by TRIzol reagent and 
quantified by the NanoDrop ND-2000 (Thermo Scientific, Waltham, MA, USA). The integrity of RNA was 
assessed using the Agilent Bioanalyzer 2100 (Agilent Technologies Inc, Santa Clara, CA, USA).
Customized Agilent Human lncRNA microarray (4 × 180 K, Design ID: 062918) was used in this study. 30,656 
probes located in mRNA transcripts from Entrez Gene and 78,243 probes in lncRNA. the catalog of the lncRNA 
were collected from the integration of Broad Institute, Human Body Map lncRNA, TUCP catalog, UCSC lncRNA 
Transcripts, GENCODE 18, NONCODE V4.0, Ensembl, RefSeq, Ultra-conserved region encoding LncRNA 
(UCR), lncRNAdb and ncRNA database. The total RNA was transcribed to double-stranded cDNA, synthe-
sized into cRNA (Low Input Quick-Amp Labeling Kit, one-color, Agilent), and labeled with Cyanine-3-CTP. 
The labeled cRNAs were then hybridized onto the microarray. After washing, the arrays were scanned by the 
Agilent Scanner G2505C (Agilent Technologies Inc., Santa Clara, CA, USA). Other parameters in ncRNA labe-
ling, microarray hybridization, and washing procedure were performed according to the manufacturer’s standard 
protocols. RT-PCR was applied to validate parts of significant differential genes within same samples with > 3 
times technical repeats.
Image scanning and data analysis. The array images were analyzed using Feature Extraction software 
(version 10.7.1.1, Agilent Technologies Inc., Santa Clara, CA, USA), and the raw data were obtained and basically 
analyzed with Genespring. The raw data were initially normalized with the quantile algorithm. The probes that at 
least in one out of two conditions had flags in “P” were chosen for further data analysis. Differentially expressed 
genes or lncRNAs were identified through a combination of fold change and p-values calculated from a t-test 
(details in the Statistical analysis section). The threshold set for upregulated and downregulated genes was a fold 
change ≥ 2.0 and a P ≤ 0.05.
Identification of cis-regulated mRNAs of the differential lncRNAs. Based on these 5 biological 
replications with or without LLDT-8 treatment, differential expressed lncRNA, cis-regulatory genes/mRNAs were 
identified. The mRNAs were identified as “cis-regulated mRNAs” when (1) the mRNA loci are within 100 k win-
dows up- and down-stream of the given lncRNA, and (2) the Pearson correlation of lncRNA–mRNA expression 
is significant (P ≤ 0.01). GO analysis and KEGG analysis were applied to determine the roles of these differentially 
expressed mRNAs. Finally, Hierarchical Clustering was performed to display the distinguishable genes’ expres-
sion pattern among samples.
Functional prediction of selected differential lncRNAs. The overall gene function distribution 
(co-expression, ontology and pathway) of the differential lncRNAs obtained in the experiment was identified as 
follows. For each differential lncRNA, the Pearson correlation of its expression value with the expression value 
of each mRNA was calculated, and a P < 0.05 was selected. The enrichment of functional terms in annotation of 
Figure 1. Flowchart of the study. In the study, we collected 5 RA joint tissues from joint replacement surgery. 
FLS cells were purified with cell culture and validated by flow cytometry assay. When cells approached 
confluence, they were passed after diluting 1:3 with fresh medium until used. The purity of the cells was verified 
by flow cytometric analysis. The FLS, from passages 4, were seeded in 6-well plates. As the control group, the 
FLS cells were cultured in DMEM including 10 ng/ml TNF-α and 10 ng/ml IL-17 (PeproTech, USA) for 12 h. 
In the treatment group, LLDT-8 (Shanghai Pharma, Shanghai) was dissolved with 2% DMSO and diluted with 
DMEM (with TNF-α and IL-17) to 100 nM for 24 hours. RT-PCR, Western blot and microarray were then 
conducted to different groups.
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differential expressing gene or co-expressed mRNAs was statistically evaluated using the hypergeometric cumu-
lative distribution function30,31.
Identification of transcription factors (TF) associated to differential lncRNAs. The transcription 
factor/chromatin regulation complexes that may possibly play a co-regulatory role with lncRNAs were identi-
fied32,33. In brief, the set between the lncRNA co-expression coding genes and the target genes of transcription 
factors/chromatin regulation complex was collected respectively. The enrichment level of the set was determined 
using hypergeometric distribution, thus the transcription factors significantly associated with differential lncR-
NAs were finally screened. Finally, the co-expression networks among lncRNA, TF, and target genes were built 
with Cytoscape 3.4.034.
Western Blot and Immunofluorescence. Western Blot and Immunofluorescence were applied to detect 
the protein expression change and nuclear localization to show the effect of LLDT-8 treatment to RF cells in our 
validation stage and the procedures are same as the previous study2. Briefly, FLS cells were seeded at a density of 
1 × 107 cells per well (6-well plates) in DMEM supplemented with 10% FBS and 1% penicillin. After cell attach-
ment, the culture medium was replaced by DMEM supplemented with A panel: DMSO (2%), B panel: TNF-α 
(10 ng/ml) and IL-17 (10 ng/ml) or C panel: TNF-α (10 ng/ml), IL-17 (10 ng/ml) and LLDT-8 (0, 50 nM, 100 nm, 
respectively) for 12 hours. The cells were collected and lysed by 1 nM PMSF SDS on ice for 30 min. The cellular 
lysates were loaded, and proteins were separated on SDS-PAGE and transferred to nitrocellulose filter. The blots 
were blocked with 5% BSA TBST for 1 h at room temperature, then probed with rabbit anti-mouse antibodies 
against p-P65(1:1000) and GAPDH (1:6000) overnight at 4 °C. After five washes, the blots were subsequently 
incubated with a HRP-linked secondary antibody (1:2500) for 90 min at room temperature. The blots were vis-
ualized by ECLTM Prime Western Blotting Detection Reagent. FLS with different treatments were fixed using 
4% (v/v) formaldehyde in PBS for 15 min and mounted onto slides using VECTASHIELD Antifade Mounting 
Medium containing DAPI (Vector Laboratories, H-1200) and visualized using an inverted SP5 confocal micro-
scope (Leica).
Statistical analysis. One sample t-test was applied to compare the mean difference of the expressed level 
before and after the treatment of LLDT-8. All the statistical analysis was made using R version 3.2.2. We selected 
the top signals using the threshold on both the fold change > 2 and the P-value < 0.05 from mRNA and lncRNA. 
In addition, we calculated the Pearson correlation for the expression values on every different combination of 
lncRNA and mRNA. The pair of IncRNA-mRNA will be selected if their correlation test reaches the threshold 
(P-value < 0.05). Also, in order to ensure the selected pairs are meaningful, we only selected the correlated pairs in 
which lncRNA plays as the inhibition of mRNA expression (correlation coefficient, r < −0.9). False discover rate 
(FDR) correction was performed by Benjamini-Hochberg procedure with default R function.
Results
Genome-wide mRNA profile of before and after LLDT-8 treatment. We describe the project 
with the flowchart as Fig. 1. By analyzing genome-wide lncRNA microarray of RA FLS responding to LLDT-8, 
we found 394 differentially expressed genes (p < 0.05, fold change > 2). 71% (281) of them were down-regu-
lated and 28.7% (113) were up-regulated (Supp. Table 1). Volcano plot for the differential express genes was 
shown in Fig. 2A. Supervised cluster analysis (Heatmap) showed differentially expressed genes could distin-
guish the samples before and after LLDT-8 treatment (Fig. 2B). In order to check the quality of the microarray 
data, we validated several canonical immune responses relate genes, such as NFKB1 (P = 1.80 × 10−10), MYD88 
(P = 1.26 × 10−25), JUN (P = 1.09 × 10−14) and FOS (P = 4.41 × 10−22) with qPCR and we found the result were 
highly consistent with microarray results (Fig. 2C). These down-regulated T-cell receptor signaling pathway 
(NFKB1, JUN, FOS) and Toll-like receptor signaling pathway (MYD88) genes indicate LLDT-8 could provide 
significantly immunosuppressive activity with multiple molecular networking approaches. KEGG pathway anal-
ysis (Fig. 2D) of the differentially expressed genes showed 20 pathways were significantly enriched (P < 0.05, 
FDR < 0.01). Interesting, the top 4 enriched pathways were significantly relevant to Immune reaction, includ-
ing cytokine-cytokine receptor interaction (P = 4.61 × 10−13), rheumatoid arthritis (P = 1.90 × 10−6), chemokine 
signaling pathway (P = 1.01 × 10−5) and TNF signaling pathway (P = 2.79 × 10−4). These findings indicated that 
the LLDT-8 would greatly influence the RA FLS in the process of immune regulation. By analyzing interaction 
networks based on STRING (Fig. 3A), BioGRID (Fig. 3B) and KEGG (Fig. 3C), we found that these differentially 
expressed genes were significantly interacting with each other and constructed specific and explicit networks 
(Fig. 3).
Genome-wide lncRNA profile of RA FLS before and after LLDT-8 treatment. The lncRNAs with 
both fold change ≥ 2.0 and P-value ≤ 0.05 from the t-test were identified as differentially expressed lncRNAs. Our 
results showed that 360 lncRNAs of RA FLS were significantly changed with LLDT-8 treatment. Those P-values 
ranged from 4.88 × 10−2 to 2.92 × 10−7, and the fold change spanned from 2.00 to 18.44. Among these lncRNAs, 
56% (203) were downregulated and 44% (157) were upregulated (Supp. Table 2). Our result indicates not only 
mRNAs but also lncRNA transcripts would be widely changed during the treatment of LLDT-8. In addition, we 
found the target genes of the differential lncRNAs that could also be a strong indication of the change caused by 
LLDT-8 treatment. In addition, as Fig. 2E shows, cluster analysis based on the 30 co-expression genes of differen-
tial lncRNA (ENST00000584923) could separate the samples quite accurately with or without LLDT-8 treatment, 
indicating that the lncRNA network and the mRNA network in the cells were highly interacted and coordinately 
changed by LLDT-8 treatment.
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Co-expression network analysis between mRNA and lncRNA. The IncRNAs co-expressed function 
was identified through the correlation of lncRNA-mRNA. For each of the lncRNA, we calculate the Pearson cor-
relation of its expression value with the expression value from every different mRNA. The pair of IncRNA and 
Figure 2. Genome-wide differential analysis for the treatment of LLDT-8 in FLS cells from RA patients. 
Volcano plot for the differential express genes. B. Heatmap plot for differential expressed genes to show the 
effect of LLDT-8 to FLS cells. C. qPCR validation to significant differential expressed genes from microarray. D. 
Gene ontology analysis to differential expressed genes (N = 3 technical repeats in control, TNF-α and LLDT8 
treatment group). TNF-α treatment is applied to simulate inflammatory reaction and then LLDT8 treatment is 
applied to check the effect of LLDT8 to inflammatory reaction. E. Heatmap plot to the co-expressed mRNA of 
differential lncRNA have the power to separate samples with or without LLDT-8 treatment.
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mRNA was selected if their correlation test reached the threshold (P-value < 0.05). Also, in order to ensure the 
selected pairs is meaningful, we only kept those correlated pairs which show strong negative correlation (corre-
lation coefficient < −0.9). Our result indicated that there were 9,666 pairs of lncRNA-mRNA with strong nega-
tive correlation. Moreover, 618 of them were also identified as the significantly differential mRNA and lncRNA 
from the t-test in which 70 pairs of them were located in the same chromosome. Furthermore, 13 out of those 
70 pairs were located in chromosome-6, and 10 out of those them were located in chromosome-17. Such kind 
of chromosome-distribution disequilibrium suggests the influence of the LLDT-8 is not a random effect but 
with specific target and influence to FLS. 27 cis-regulated (Table 2 and Supp. Table 3) and 591 trans-regulated 
lncRNA-mRNAs modules were identified (Table 3 and Supp. Table 4).
Functional prediction of selected differential lncRNAs analysis were conducted both with GO and KEGG 
strategies. Gene Ontology analysis showed that the term of innate immune responses was significantly enriched 
and 17 differential lncRNAs were identified to be involved (Supp. Table 5). KEGG analysis identified term of rheu-
matoid arthritis was significant enriched and 4 differential lncRNAs (NONHSAG028996, NONHSAT142637, 
ENST00000584934 and NR_028330.1) were identified to be involved (Supp. Table 6).
We also identified large number of co-expressed lncRNA and TFs. The co-expression network between TF 
and lncRNA was shown in Fig. 4A. We discovered one large sub-network and large number isolated interaction 
between TFs and lncRNA. This network indicated lncRNA and TF would regulate the gene expression together 
in FLS cells. When we build lncRNA, TF, target gene network together (Fig. 4B), the result is quite similar as our 
expectation, and large numbers of genes were identified regulated by lncRNA and TF simultaneously.
Cellular regulation effect of LLDT-8 treatment to FLS involved in NF-κB pathway. In order 
to validate our discoveries that LLDT-8 could provide pharmacological effect to RA therapy via the interac-
tion with rheumatology related pathway (Fig. 2D), we validate the effect of LLDT-8 to one of most important 
Figure 3. Interaction network analysis to differential expression genes based on STRING, BioGRID and KEGG. 
(A) Evidence view with STRING 9.0, (B) BioGRID based Network, (C) KEGG based network.
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rheumatology related pathway, NF-kappa B signaling pathway. Western-blot shown that the protein level of p-p65 
are strongly inhibited with increasing concentration of LLDT-8 treatment to FLS cells stimulated by TNF-α and 
IL-17 (Fig. 5A). In addition, we also demonstrate that LLDT-8 would inhibit the nuclear translocation of the p65 
(Fig. 5B) which is the significant effect of TNF and IL-17, indicating LLDT-8 has significant inhibition to TNF 
and IL-17 effects and therefore have potential pharmacological effect to RA therapy.
Discussion
Tripterygium is a traditional Chinese medicine, which has widely been used in the treatment of rheumatic disease. 
(5R)-5-hydroxytriptolide (LLDT-8) is an extracted compound from Tripterygium and has been showed lower 
cytotoxicity and relatively higher immunosuppressive activity. However, how LLDT-8 influences RA FLS cells 
is still unknown, especially in the level of lncRNAs. In this study of genome-wide microarray assay, we identi-
fied large number of lncRNA and mRNAs responding to the LLDT-8 treatment. In addition, the first LLDT-8 
lncRNA Coordination P FC Regulation
Gene 
Symbol P-value FC Regulation P R
FR264384 chr9:2653919–2654254 1.03 × 10−2 2.67 down NINJ1 2.30 × 10−5 2.4 up 2.40 × 10−4 −0.9
LINC00473 chr6:166352947-166401527 1.86 × 10−2 2.48 down HSPA1B 7.52 × 10−4 3 up 2.16 × 10−4 −0.9
linc-C20orf111-BP chr20:42839626-42855166 4.99 × 10−4 2.02 up SPTLC3 6.30 × 10−4 2 down 1.08 × 10−4 −0.9
linc-DHX37-4 chr12:127215097-127221919 6.24 × 10−4 2.73 up TENC1 4.70 × 10−4 2.1 down 1.30 × 10−4 −0.9
linc-SCYL1-2 chr11:65222664-65234212 2.97 × 10−3 2.56 up FTH1 2.82 × 10−4 1.9 down 1.51 × 10−4 −0.9
linc-SLC35F5-2 chr2:114579399-114647368 3.80 × 10−3 2.17 up EHD3 1.13 × 10−3 2.7 down 2.85 × 10−4 −0.9
linc-TAGAP-1 chr6:160007988-160015671 2.43 × 10−6 5.10 up GJA1 1.72 × 10−3 2.5 down 2.78 × 10−4 −0.9
PRLR chr5:35048860-35118224 1.50 × 10−3 3.46 up SPINK13 1.75 × 10−3 2.6 down 2.38 × 10−4 −0.9
RP11-356I2.4-006 chr6:138175999-138179185 1.66 × 10−4 6.64 up PRDM1 1.77 × 10−3 1.9 down 1.06 × 10−4 −0.9
RP11-809O17.1-002 chr8:142136390-142140060 2.84 × 10−3 2.09 up PNMA2 1.46 × 10−3 2.4 down 2.51 × 10−4 −0.9
SLC16A7 chr12:60083117-60183635 9.31 × 10−4 2.34 down VAMP1 2.01 × 10−5 2.3 up 1.53 × 10−4 −0.9
SNORD3A-001 chr17:19091329-19092027 4.55 × 10−5 11.0 down CCR10 5.00 × 10−5 2.8 up 2.17 × 10−4 −0.9
SNORD3A-001 chr17:19091329-19092027 4.55 × 10−5 11.0 down HEXIM2 3.21 × 10−3 2.1 up 2.88 × 10−4 −0.9
SPECC1L-ADORA2A chr22:24666784-24838328 4.18 × 10−5 2.80 up TIMP3 9.58 × 10−4 2.2 down 1.09 × 10−4 −0.9
TNFRSF10B chr8:22877647-22926700 5.39 × 10−4 2.14 up PLEKHA2 2.59 × 10−3 3.3 down 1.90 × 10−4 −0.9
TNFRSF10B chr8:22877647-22926700 5.39 × 10−4 2.14 up SNTB1 9.75 × 10−6 3.4 down 1.12 × 10−4 −0.9
WISP1 chr8:134203281-134243932 1.26 × 10−4 5.31 down SLCO5A1 3.70 × 10−4 3.6 up 1.72 × 10−4 −0.9
Table 2. Most significant trans-lncRNA-mRNA regulation pairs for the significant differential lncRNA. 
Footnote: Coordination is based on GRCh37. P-valueA indicate the significance of the differential expression 
while P-valueB indicate the significance of the correlation between lncRNA and gene expression. Abbreviation: 
FC, Fold change; R, Correlation coefficient.
lncRNA Coordination P-valueA FC R Gene Symbol P-value FC Regualation P-valueB R
FR407458 chr7:100770384-100771815 1.82 × 10−2 2.1 down TIAM2 6.42 × 10−4 2.15 up 1.01 × 10−4 −0.9
AC005682.8-001 chr7:22928990-22980809 2.71 × 10−3 4.1 up KIAA0226L 2.17 × 10−3 3.25 down 1.01 × 10−4 −0.9
PLCB1-IT1-001 chr20:8229372-8237564 7.08 × 10−3 2.1 down HSPA1A 3.44 × 10−4 3.02 up 1.01 × 10−4 −0.9
CXCL1 chr4:74735108-74737019 4.92 × 10−5 2.6 down TNFRSF18 1.47 × 10−3 4.59 up 1.01 × 10−4 −0.9
RP11-356I2.4-006 chr6:138175999-138179185 1.66 × 10−4 6.6 up CYP24A1 7.06 × 10−5 9.65 down 1.03 × 10−4 −0.9
NKX3-1 chr8:23536205-23540434 5.49 × 10−4 3.9 up G0S2 3.05 × 10−4 2.84 down 1.03 × 10−4 −0.9
FR018579 chr10:63664416-63664655 1.13 × 10−2 2.3 down NEK10 1.45 × 10−3 2.21 up 1.03 × 10−4 −0.9
HNRNPDL chr4:83343716-83351378 7.53 × 10−3 2.1 down N4BP2L1 6.45 × 10−4 2.17 up 1.03 × 10−4 −0.9
FR066129 chr4:74608854-74609068 1.11 × 10−4 4.3 down PHLDA2 2.28 × 10−4 3.3 up 1.04 × 10−4 −0.9
RP11-356I2.4-006 chr6:138175999-138179185 1.66 × 10−4 6.6 up CCL8 2.48 × 10−4 17.2 down 1.04 × 10−4 −0.9
TRIB2 chr2:12856997-12882858 5.35 × 10−3 2 down LOC727916 2.36 × 10−3 3.41 up 1.04 × 10−4 −0.9
FR264384 chr9:2653919-2654254 1.03 × 10−2 2.7 down FAM129A 6.45 × 10−3 2.08 up 1.04 × 10−4 −0.9
linc-TRIM29-3 chr11:121899038-121908990 9.03 × 10−4 2 up G0S2 3.05 × 10−4 2.84 down 1.05 × 10−4 −0.9
linc-DHX37-4 chr12:127215097-127221919 6.67 × 10−4 3.2 up KIAA0226L 2.17 × 10−3 3.25 down 1.05 × 10−4 −0.9
RP11-356I2.4-006 chr6:138175999-138179185 1.67 × 10−4 6.6 up LXN 2.68 × 10−4 2.83 down 1.05 × 10−4 −0.9
Table 3. Most significant cis-lncRNA-mRNA regulation pairs for the significant differential lncRNA Footnote: 
Coordination is based on GRCh37. P-valueA indicate the significance of the differential expression while 
P-valueB indicate the significance of the correlation between lncRNA and gene expression. Abbreviation: FC, 
Fold change; R, Correlation coefficient.
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related cis-regulated and trans-regulated lncRNA-mRNA modules were identified. We also constructed the first 
lncRNA-TF-mRNA co-expression network and demonstrated that LLDT-8 influenced the expression network 
within the whole FLS cells and therefore provided potential molecular and cellular mechanisms that LLDT-8 
could be considered as potential rheumatoid arthritis drugs.
As we know, this is the first study to elaborate the genome-wide lncRNA and mRNA changes with or without 
LLDT-8 treatment. Our study provided an important landscape to design further studies to investigate the medi-
cal applications for lncRNAs in RA therapy. Although, genome-wide association studies (GWAS) have identified 
hundreds of variants associated with RA, our understanding of the disease mechanisms is still limited. Notably, 
more than 90% of the risk variants lie in non-coding regions, and almost 10% are corresponding to lncRNA 
Figure 4. Co-expression network of lncRNA-TF and lncRNA-TF-targetGene within LLDT-8 differential 
response transcriptional regulatory network. (A) Co-expression network of lncRNA-TF, (B) Co-expression 
network of lncRNA-TF-Target Genes.
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regions23,35,36. Considering that our result showed the significant change of the lncRNA during LLDT-8 treatment, 
lncRNA would be play important role in the pathogenesis and therapy of RA.
Our microarray data are consistent with protein results in our previous study in which we found LLDT-8 
inhibited IL-1β, IL-6, IL-21 and IL-23 while LLDT-8 increased the IL-10 protein level. Meanwhile, our research 
were supported by numerous of previous research, such as Dr. Karouzakis and colleagues found synovial fibro-
blasts from early rheumatoid arthritis shown DNA methylation changes37. Our research demonstrate the immu-
nosuppressive function of LLDT-8 was related to the interaction with ncRNA network. Our results were also 
consistent with n’sh (PMC2833606) in which they found CCL8 are abundantly-expressed in RA synovial tissue 
while we found LLDT-8 could significant decrease CCL8 (Table 3). In another study38, p38 MAPK inhibition 
treatment showed increased TNFRSF18 which is similar with LLDT-8 treatment in our study which also high-
lights the anti-inflammatory function of LLDT-838. What’s more, FAM129A was demonstrated low-expression 
in RSK2 deficiency mice which have earlier and exacerbated inflammation of bone destruction and in our study, 
we found FAM129A was significantly up-regulated after LLDT-8 treatment39. All these evidence support our 
conclusion that LLDT-8 own immune-suppressive function and epigenetic regulation mediated by lncRNA might 
play important roles.
We conducted the power analysis to estimate the minimum samples size to identify significant (q-value < 0.5) 
mRNA changes based on our dataset GSE84074 with bootstrap resampling. In the bootstrap resampling, we 
selected several important rheumatoid arthritis genes such as MMP genes (MMP1, MMP3), CCL genes (CCL3, 
CCL4, and CCL26), and IL genes (IL6, IL8, IL19, and IL24). We found when the sample size is larger than 4, 
majority of these rheumatoid arthritis genes can be detected with power > 0.8 (Supplementary Fig. 2), therefore, 
we believe our sample size is sufficient to identify the most interesting inflammation and autoimmune associated 
signals.
Our study also provided a probability to compare the lncRNA profiles with RA, primary Sjögren’s syndrome40, 
gastric carcinogenesis41, endometrial carcinoma42, bladder cancer43, esophageal squamous cell carcinoma44, 
non-small-cell lung cancer45 and cervical cancer46, since our data has been deposited to GEO database. These 
diseases might share some common aberrant lncRNAs relevant with inflammation and immune response and 
therefore provide some special insight to the therapy of RA.
In summary, our results provided a good prospect in further clinical tests of LLDT-8 for its therapeutic poten-
tial in the treatment of RA. We also suggest that more studies need to be done in order to further investigate the 
biological functions of IncRNAs in more patient samples. However, those initial results suggest that lncRNA 
would be a good biomarker and drug target in the future drug discovery, especially for LLDT-8. Our study also 
demonstrate epigenetics including DNA methylation47–49 and lncRNA50,51 are playing important roles in etiology 
and therapy of RA.
Conclusion
Genome-wide lncRNA and transcriptome analysis of response to treatment with (5R)-5-Hydroxytriptolide 
(LLDT-8) in cells shown LLDT-8 would mainly influence the RA cells systemically and especially in the process 
of immune network regulation.
Data Availability
The microarray data was deposited in the Gene Expression Omnibus (GEO accession: GSE84074).
Figure 5. Western Blot and Immunofluorescence to show LLDT-8 effect on p-P65 protein gene expression and 
nuclear transform. (A) Western blot to show the suppressive functions of LLDT-8 to p-p65 protein in different 
dose (10 ng/ml, 50 ng/ml and 100 ng/ml). (B) Immunefluorescence and confocal microscopy to show the 
suppressive function of LLDT-8 to the nuclear transform of p-p65.
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